You are here

FDA Approves Tecentriq for Adults With Extensive-Stage Small Cell Lung Cancer

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC

The FDA has approved atezolizumab (Tecentriq, Genentech) in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

The approval was based on results from the IMpower133 study which demonstrated that atezolizumab combined with chemotherapy significantly extended the lives of patients with ES-SCLC compared to chemotherapy alone. In addition, the combination treatment significantly lowered the risk of disease worsening or death compared to chemotherapy alone.

ES-SCLC is a highly aggressive, difficult-to-treat form of lung cancer with few treatment advances over the last two decades. According to the American Cancer Society, approximately 70% of people with SCLC are diagnosed with ES-SCLC.

Atezolizumab is also approved in combination with bevacizumab, paclitaxel, and carboplatin for the initial treatment of adults with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. In addition, Atezolizumab is approved for adults with metastatic NSCLC with disease progression during or after platinum-containing chemotherapy.

IMpower133, a phase 3, multicenter, double-blinded, randomized placebo-controlled study, evaluated the efficacy and safety of atezolizumab in combination with chemotherapy (carboplatin and etoposide) versus chemotherapy (carboplatin and etoposide) alone in chemotherapy-naïve adults with ES-SCLC.

The most common adverse reactions in people receiving atezolizumab plus chemotherapy were fatigue/asthenia, nausea, alopecia, decreased appetite, constipation, and vomiting.

Atezolizumab is also approved to treat urothelial carcinoma and triple-negative breast cancer.

Source: Genentech, March 18, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Drug Improved or Stabilized Symptoms, Shrank Brain Lesions